News for TTOO Stock

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens T2 Biosystems Announces Third Quarter 2024 Financial Results T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024 T2 Biosystems to Host Business Update Call on October 10, 2024 T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients T2 Biosystems Provides Updates on its New Product Development Pipeline Progress T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference T2 Biosystems to Attend Upcoming Investor Conferences T2 Biosystems Announces Second Quarter 2024 Financial Results T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024 T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease T2 Biosystems Announces First Quarter 2024 Financial Results T2 Biosystems Announces Commercial Expansion Through Middle East Distributor T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024 U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum T2 Biosystems Regains Compliance with Nasdaq Listing Requirements T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii T2 Biosystems Announces Reverse Stock Split Effective Today T2 Biosystems Reports Granting of Inducement Award T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023 T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel T2 Biosystems Reports Granting of Inducement Award T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement T2 Biosystems Announces Second Quarter 2023 Financial Results T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements T2 Biosystems to Attend Upcoming Investor Conferences T2 Biosystems to Report Second Quarter 2023 Financial Results on August 7, 2023 T2 Biosystems Reports Granting of Inducement Award T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History T2 Biosystems Announces First Quarter 2023 Financial Results T2 Biosystems Announces Exploration of Strategic Alternatives and the Implementation of a Restructuring Program T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023 WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023 T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results T2 Biosystems to Report First Quarter 2023 Financial Results on May 15, 2023 T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023 T2 Biosystems Announces Pricing of $12 Million Public Offering T2 Biosystems Announces Proposed Public Offering T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation’s LymeX Diagnostics Prize T2 Biosystems Reports Granting of Inducement Award T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc. T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy T2 Biosystems Announces Third Quarter 2022 Financial Results T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022 T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook T2 Biosystems Announces Reverse Stock Split Effective Today T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million T2 Biosystems Announces Commercial Expansion Through Distributor in Baltic Region T2 Biosystems to Participate in the H.C. Wainwright Global Investment Conference T2 Biosystems to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase T2 Biosystems Announces Second Quarter 2022 Financial Results T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus T2 Biosystems Reports Granting of Inducement Awards T2 Biosystems to Report Second Quarter 2022 Financial Results on August 15, 2022 T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results T2 Biosystems to Appear on the Benzinga All Access Show on June 17, 2022 T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market T2 Biosystems Announces Issuance of U.S. Patent for Direct Detection of Lyme Disease T2 Biosystems Announces First Quarter 2022 Financial Results T2 Biosystems Announces Receipt of Nasdaq Delisting Notice T2 Biosystems Announces Formation and Members of Scientific Advisory Board T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel T2 Biosystems to Report First Quarter 2022 Financial Results on May 5, 2022 T2 Biosystems Reports Granting of Inducement Award T2 Biosystems Announces BARDA Exercise of Contract Option 2B Valued at $4.4 Million T2 Biosystems to Host Analyst and Investor Day on April 12, 2022 T2 Biosystems Announces Fourth Quarter & Full Year 2021 Financial Results T2 Biosystems Announces Commercial Expansion Through Distributors in Norway, Finland and Türkiye T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement T2 Biosystems to Report Fourth Quarter and Full Year 2021 Financial Results on February 17, 2022 T2 Biosystems Reports Granting of Inducement Award T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Subvariants T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Variant T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum T2 Biosystems Participates in the World Anti-Microbial Resistance Congress T2 Biosystems Announces Third Quarter 2021 Financial Results T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer T2 Biosystems to Report Third Quarter 2021 Financial Results on November 4, 2021 T2 Biosystems Announces Distribution Agreements in Key Asia-Pacific Markets T2 Biosystems Appoints Laura Adams to Its Board of Directors Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors T2 Biosystems Reports Granting of Inducement Award T2 Biosystems Showcases Research from Recent Industry Conferences T2 Biosystems Announces BARDA Exercise of Contract Option 2A Valued at $6.4 Million T2 Biosystems to Unveil New Data at September Conferences T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus T2 Biosystems Announces Plans to Consolidate and Expand Facilities in Massachusetts T2 Biosystems Recognizes Sepsis Awareness Month with Thought Leadership Campaign and Participation in Sepsis Alliance Health Equity Pledge T2 Biosystems Announces Second Quarter 2021 Financial Results T2 Biosystems to Participate in the Canaccord Genuity 41st Annual Growth Conference T2 Biosystems to Report Second Quarter 2021 Financial Results on August 5, 2021 T2 Biosystems Reports Granting of Inducement Award T2 Biosystems to Participate at Clinical Conferences in June and July 2021 T2 Biosystems Reminds Stockholders to Vote at the Upcoming Annual Meeting T2 Biosystems Announces First Quarter 2021 Financial Results T2 Biosystems Accelerates Product Development Initiatives Under Existing BARDA Contract T2 Biosystems Announces Meta-analysis of Controlled Studies in Peer-Reviewed Medical Journal Highlighting the Benefits of T2MR Technology Compared to Blood Culture T2 Biosystems to Report First Quarter 2021 Financial Results on May 6, 2021 T2 Biosystems CEO Shares Personal Heart Transplant and Sepsis Survival Story in Newly Released Book T2 Biosystems Reports Granting of Inducement Award T2 Biosystems Announces Fourth Quarter & Full Year 2020 Financial Results T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021 T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus T2 Biosystems Reports Granting of Inducement Award T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2020 Results T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum T2 Biosystems Announces Third Quarter 2020 Financial Results Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020 T2 Biosystems to Participate in Sepsis Alliance Summit T2 Biosystems Announces CMS Approval of a New Technology Add-On Payment for the T2Bacteria® Panel for a Second Year T2 Biosystems Receives FDA Emergency Use Authorization for COVID-19 Molecular Diagnostic Test T2 Biosystems to Report Second Quarter 2020 Financial Results on August 11, 2020 T2 Biosystems Announces Preliminary Second Quarter 2020 Financial Results T2 Biosystems Announces First Quarter 2020 Financial Results T2 Biosystems Announces U.S. Launch of COVID-19 Diagnostic Test T2 Biosystems Announces Changes to Board of Directors